Page 2191 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 130 Acquired Disorders of Platelet Function 1943.e1

REFERENCES 26. Verschuren JJ, Jukema JW: Pharmacogenetics of antiplatelet therapy:
ready for clinical application? Heart 97:1268, 2011.
1. Koscielny J, Ziemer S, Radtke H, et al: A practical concept for preop- 27. Snoep JD, Hovens MM, Eikenboom JC, et al: Association of
erative identification of patients with impaired primary hemostasis. Clin laboratory-defined aspirin resistance with a higher risk of recurrent
Appl Thromb Hemost 10:195, 2004. cardiovascular events: a systematic review and meta-analysis. Arch Intern
2. Patrono C, Coller B, Dalen JE, et al: Platelet-active drugs: the relation- Med 167:1593, 2007.
ships among dose, effectiveness, and side effects. Chest 119:39S, 2001. 28. Krasopoulos G, Brister SJ, Beattie WS, et al: Aspirin “resistance” and
3. Hovav T, Goldfarb A, Artmann G, et al: Enhanced adherence of risk of cardiovascular morbidity: systematic review and meta-analysis.
b-thalassaemic erythrocytes to endothelial cells. Br J Haematol 106:178, BMJ 336:195, 2008.
1999. 29. Schwartz KA, Schwartz DE, Ghosheh K, et al: Compliance as a critical
4. Mackowiak PA: Brief history of antipyretic therapy. Clin Infect Dis consideration in patients who appear to be resistant to aspirin after
31(Suppl 5):S154–S156, 2000. healing of myocardial infarction. Am J Cardiol 95:973, 2005.
5. Miner J, Hoffhines A: The discovery of aspirin’s antithrombotic effects. 30. Lev EI, Patel RT, Maresh KJ, et al: Aspirin and clopidogrel drug
Tex Heart Inst J 34:179, 2007. response in patients undergoing percutaneous coronary intervention:
6. Undas A, Brummel-Ziedins KE, Mann KG: Antithrombotic properties the role of dual drug resistance. J Am Coll Cardiol 47:27, 2006.
of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. 31. Gurbel PA, Bliden KP, DiChiara J, et al: Evaluation of dose-related
Blood 109:2285, 2007. effects of aspirin on platelet function: results from the Aspirin-Induced
7. Steering Committee of the Physician’s Health Study Research Group: Platelet Effect (ASPECT) study. Circulation 115:3156, 2007.
Final report of the asprin component of the ongoing physicians’ health 32. Mehta SR, Tanguay JF, Eikelboom JW, et al: Double-dose versus
study. N Engl J Med 321:1989. standard-dose clopidogrel and high-dose versus low-dose aspirin in
8. Eikelboom JW, Hirsh J, Spencer FA, et al: Antiplatelet drugs: Anti- individuals undergoing percutaneous coronary intervention for acute
thrombotic Therapy and Prevention of Thrombosis, 9th ed: American coronary syndromes (CURRENT-OASIS 7): a randomised factorial
College of Chest Physicians Evidence-Based Clinical Practice Guide- trial. Lancet 376:1233, 2010.
lines. Chest 141:e89S, 2012. 33. Alberts MJ: Platelet function testing for aspirin resistance is reasonable
9. Kallmann R, Nieuwenhuis HK, de Groot PG, et al: Effects of low doses to do: yes! Stroke 41:2400, 2010.
of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane 34. Guthikonda S, Lev EI, Patel R, et al: Reticulated platelets and unin-
production and 6-keto-PGF1 a excretion in healthy subjects. Thromb hibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
Res 45:355, 1987. J Thromb Haemost 5:490, 2007.
10. Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and 35. Cipollone F, Fazia ML: COX-2 and atherosclerosis. J Cardiovasc Phar-
inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24:246, macol 47(Suppl 1):S26–S36, 2006.
2004. 36. Patrono C, Baigent C, Hirsh J, et al: Antiplatelet drugs: American
11. Weksler BB: Regulation of prostaglandin synthesis in human vascular College of Chest Physicians Evidence-Based Clinical Practice Guide-
cells. Ann N Y Acad Sci 509:142–148, 1987. lines (8th Edition). Chest 133:199S, 2008.
12. Weiss HJ, Aledort LM: Impaired platelet-connective-tissue reaction in 37. Catella-Lawson F, Reilly MP, Kapoor SC, et al: Cyclooxygenase
man after aspirin ingestion. Lancet 2:495, 1967. inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809,
13. Kyrle PA, Westwick J, Scully MF, et al: Investigation of the interaction 2001.
of blood platelets with the coagulation system at the site of plug forma- 38. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxy-
tion in vivo in man–effect of low-dose aspirin. Thromb Haemost 57:62, genase 1: effects on response to aspirin. Clin Pharmacol Ther 73:122,
1987. 2003.
14. Undas A, Brummel K, Musial J, et al: Blood coagulation at the site of 39. Goodman T, Ferro A, Sharma P: Pharmacogenetics of aspirin resistance:
microvascular injury: effects of low-dose aspirin. Blood 98:2423, 2001. a comprehensive systematic review. Br J Clin Pharmacol 66:222, 2008.
15. Szczeklik A, Musial J, Undas A, et al: Inhibition of thrombin generation 40. Voora D, Horton J, Shah SH, et al: Polymorphisms associated with
by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc in vitro aspirin resistance are not associated with clinical outcomes in
Biol 16:948, 1996. patients with coronary artery disease who report regular aspirin use. Am
16. Roderick PJ, Wilkes HC, Meade TW: The gastrointestinal toxicity of Heart J 162:166, 2011.
aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 41. Würtz M, Kristensen SD, Hvas AM, et al: Pharmacogenetics of the
35:219, 1993. antiplatelet effect of aspirin. Curr Pharm Des 18:5294, 2012.
17. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of 42. Michelson AD: P2Y12 antagonism: promises and challenges. Arterio-
nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888, 1999. scler Thromb Vasc Biol 28:s33–s38, 2008.
18. Lee M, Cryer B, Feldman M: Dose effects of aspirin on gastric prosta- 43. Dorsam RT, Kunapuli SP: Central role of the P2Y12 receptor in platelet
glandins and stomach mucosal injury. Ann Intern Med 120:184, 1994. activation. J Clin Invest 113:340, 2004.
19. Wallace JL, Ma L: Inflammatory mediators in gastrointestinal defense 44. Solet DJ, Zacharski LR, Plehn JF: The role of adenosine 5’-diphosphate
and injury. Exp Biol Med (Maywood) 226:1003, 2001. receptor blockade in patients with cardiovascular disease. Am J Med
20. Feldman M, Shewmake K, Cryer B: Time course inhibition of gastric 111:45, 2001.
and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol 45. Gachet C: ADP receptors of platelets and their inhibition. Thromb
Gastrointest Liver Physiol 279:G1113–G1120, 2000. Haemost 86:222, 2001.
21. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin 46. Taka T, Okano E, Seki J, et al: Effects of clopidogrel on platelet activa-
therapy on gastric, duodenal, and rectal prostaglandin levels and on tion and coagulation of non-anticoagulated rat blood under high shear
mucosal injury in healthy humans. Gastroenterology 117:17, 1999. stress. Haemostasis 29:189, 1999.
22. Sibilia J, Ravaud P, Marck G: [Risk factors for gastrointestinal bleeding 47. Curtin R, Fox D, Fitzgerald D: Clopidogrel and ticlopidine, Platelets.
associated with low-dose aspirin]. Presse Med 32:S9, 2003. San Diego, CA, 2002, Academic Press, pp 787–801.
23. Ma L, Elliott SN, Cirino G, et al: Platelets modulate gastric ulcer 48. Ostrowska M, Adamski P, Kozinski M, et al: Off-target effects of
healing: role of endostatin and vascular endothelial growth factor glycoprotein IIb/IIIa receptor inhibitors. Cardiol J 21:458, 2014.
release. Proc Natl Acad Sci USA 98:6470, 2001. 49. Armstrong PC, Peter K: GPIIb/IIIa inhibitors: from bench to bedside
24. Stuart MJ, Miller ML, Davey FR, et al: The post-aspirin bleeding time: and back to bench again. Thromb Haemost 107:808, 2012.
a screening test for evaluating haemostatic disorders. Br J Haematol 50. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al: b 3 -integrin-
43:649, 1979. deficient mice are a model for Glanzmann thrombasthenia showing
25. Hovens MM, Snoep JD, Eikenboom JC, et al: Prevalence of persistent placental defects and reduced survival. J Clin Invest 103:229, 1999.
platelet reactivity despite use of aspirin: a systematic review. Am Heart 51. Mascelli MA, Lance ET, Damaraju L, et al: Pharmacodynamic profile
J 153:175, 2007. of short-term abciximab treatment demonstrates prolonged platelet